Cargando…
SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
INTRODUCTION: Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of the low incidence of FG, data from clinical trials may be insuf...
Autores principales: | Wang, Tongtong, Patel, Shrita M., Hickman, Anne, Liu, Xinyue, Jones, Philip LStJ, Gantz, Ira, Koro, Carol E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048884/ https://www.ncbi.nlm.nih.gov/pubmed/32052281 http://dx.doi.org/10.1007/s13300-020-00771-8 |
Ejemplares similares
-
Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
por: Chowdhury, Tutul, et al.
Publicado: (2022) -
Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019) -
Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report
por: Ellegård, Lisa, et al.
Publicado: (2020) -
Fournier Gangrene
por: Wolf, Chelsea T., et al.
Publicado: (2010) -
Fournier’s gangrene
por: Cheung, Phoebe S. Y., et al.
Publicado: (2009)